Phase I Trial of Combination Chemotherapy of Pemetrexed (PEM) Plus Cisplatin (CDDP) and Concurrent Thoracic Radiotherapy (TRT) Followed by PEM Consolidation Therapy in Patients with Locally Advanced Non-Squamous (NON-SQ) Non-Small-Cell Lung Cancer (NSCLC): Post-Hoc Analysis for Progression-Free Survival (PFS) and Recurrent Sites
Seiji Niho(Dokkyo Medical University), Tomohide Tamura(St. Luke's International Hospital), Noboru Yamamoto(Tokyo National Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Keiji Nihei(Osaka Medical and Pharmaceutical University), Kōichi Goto(National Cancer Center Hospital East), Hironobu Ohmatsu(National Cancer Center Hospital East), Ikuo Sekine(University of Tsukuba), Hidehito Horinouchi(Tokyo National Hospital), Tetsuo Akimoto(Tokyo Women's Medical University), Yuichiro Ohe(National Cancer Center), Kaoru Kubota(Nippon Medical School Hospital), Kiyotaka Yoh(National Cancer Center Hospital East), Hiroshi Nokihara(Tokushima University Hospital)
Cited by 0
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835